ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Pharmaceuticals

Japan's AnGes aims to release coronavirus vaccine by end of year 

Clinical trial to begin in July as firm races to catch up with rivals in US and China

An AnGes researcher works in a company lab developing a DNA vaccine for the coronavirus on May 16. The company was able to move up the start of clinical trials from September to July.  (Nikkei Montage/ Source photo by Kyodo and AnGes)

TOKYO -- Japanese biotech venture AnGes is set to begin a clinical trial of a coronavirus vaccine in July, Nikkei learned Monday, raising hopes that the medication could secure government approval by the end of the year. 

The clinical trial was originally slated to start in September, but the Ibaraki, Osaka Prefecture-based company has been able to bring forward the schedule, following discussions with regulators and hospitals, thanks to promising results from animal tests, company officials said. 

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more